Cardiomyopathy is a manifestation of transthyretin amyloidosis (ATTR), which is an
underrecognized systemic disease whereby the transthyretin protein misfolds to form fibrils …

Recent years have seen unprecedented activity in the development of RNA-silencing
oligonucleotide therapeutics for metabolic diseases. Improved oligonucleotide design and …

ATTR amyloidosis is caused by the deposition of transthyretin in the form of amyloid fibrils in
virtually every organ of the body, including the heart. This systemic deposition leads to a …

Amyloidosis is a pathologic and clinical condition resulting from the accumulation of
insoluble aggregates of misfolded proteins in tissues. Extracellular deposition of amyloid …

Each of the 30 human amyloid diseases is associated with the aggregation of a particular
precursor protein into amyloid fibrils. In transthyretin amyloidosis (ATTR), mutant or wild-type …

Biomolecular assembly is a key driving force in nearly all life processes, providing structure,
information storage, and communication within cells and at the whole organism level. These …

Transthyretin cardiac amyloidosis (ATTR-CA) causes a restrictive cardiomyopathy in older
adults, often diagnosed at advanced stages when emerging therapies in late phase clinical …

Transthyretin (TTR) amyloidoses are systemic diseases associated with TTR aggregation
and extracellular deposition in tissues as amyloid. The most frequent and severe forms of …

Background Transthyretin amyloidosis (ATTR) is often associated with cardiac involvement
manifesting as conduction disease as well as restrictive cardiomyopathy causing heart …

Introduction: Hereditary transthyretin-mediated amyloidosis (ATTRv; v for variant) is an
underdiagnosed, progressive, and fatal multisystemic disease with a heterogenous clinical …